Idenix Pharmaceuticals, Inc.
20 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
11
Ending by 2030
Feb 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 18, 2027The maintenance fee for 3′,5′-cyclic phosphoramidate prodrugs for HCV infection (US 9,109,001) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
- 3 fees due May 17 to 24, 2027 · next May 17
- 1 fee due Jul 26, 2027The maintenance fee for Compounds and pharmaceutical compositions for the treatment of viral infections (US 9,243,025) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.
- 1 fee due Sep 15, 2027The maintenance fee for Macrocyclic serine protease inhibitors (US 9,284,307) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,951,789 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections In force · High confidence | In force | High confidence | |
| US 7,608,600 | Modified 2' and 3'-Nucleoside Prodrugs for Treating Flaviviridae Infections In force · Medium confidence | In force | Medium confidence | |
| US 7,902,202 | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections In force · High confidence | In force | High confidence | |
| US 7,781,576 | Process for preparing a synthetic intermediate for preparation of branched nucleosides In force · From the USPTO record | In force | From the USPTO record | |
| US 7,932,240 | Phosphadiazine HCV polymerase inhibitors IV In force · From the USPTO record | In force | From the USPTO record | |
| US 8,093,379 | Macrocyclic serine protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,003,659 | Macrocyclic serine protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,993,595 | Macrocyclic Serine Protease Inhibitors In force · Medium confidence | In force | Medium confidence | |
| US 8,193,372 | Phosphothiophene and phosphothiazole HCV polymerase inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,362,068 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 27: 20 patents in force now held by others · 22 lapsed for an unpaid fee · 44 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
17 abandoned · 34 no status recorded